277 related articles for article (PubMed ID: 35386324)
21. Amphiphilic Polyelectrolyte Graft Copolymers Enhance the Activity of Cyclic Dinucleotide STING Agonists.
Nguyen DC; Shae D; Pagendarm HM; Becker KW; Wehbe M; Kilchrist KV; Pastora LE; Palmer CR; Seber P; Christov PP; Duvall CL; Wilson JT
Adv Healthc Mater; 2021 Jan; 10(2):e2001056. PubMed ID: 33225632
[TBL] [Abstract][Full Text] [Related]
22. Combination of a STING Agonist and Photothermal Therapy Using Chitosan Hydrogels for Cancer Immunotherapy.
Chen C; Hu M; Cao Y; Zhu B; Chen J; Li Y; Shao J; Zhou S; Shan P; Zheng C; Li Z; Li Z
Biomacromolecules; 2023 Jun; 24(6):2790-2803. PubMed ID: 37125731
[TBL] [Abstract][Full Text] [Related]
23. Systemic nano-delivery of low-dose STING agonist targeted to CD103+ dendritic cells for cancer immunotherapy.
Doshi AS; Cantin S; Prickett LB; Mele DA; Amiji M
J Control Release; 2022 May; 345():721-733. PubMed ID: 35378213
[TBL] [Abstract][Full Text] [Related]
24. 2',4'-LNA-Functionalized 5'-S-phosphorothioester CDNs as STING agonist.
Yeboah SK; Zigli A; Sintim HO
Chembiochem; 2024 May; ():e202400321. PubMed ID: 38720428
[TBL] [Abstract][Full Text] [Related]
25. Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy.
Motedayen Aval L; Pease JE; Sharma R; Pinato DJ
J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33081170
[TBL] [Abstract][Full Text] [Related]
26. pH-Responsive STING-Activating DNA Nanovaccines for Cancer Immunotherapy.
Zhang Y; Shen T; Zhou S; Wang W; Lin S; Zhu G
Adv Ther (Weinh); 2020 Sep; 3(9):. PubMed ID: 34337143
[TBL] [Abstract][Full Text] [Related]
27. Cytosolic Delivery of Thiolated Mn-cGAMP Nanovaccine to Enhance the Antitumor Immune Responses.
Chen C; Tong Y; Zheng Y; Shi Y; Chen Z; Li J; Liu X; Zhang D; Yang H
Small; 2021 Apr; 17(17):e2006970. PubMed ID: 33719177
[TBL] [Abstract][Full Text] [Related]
28. Induction of tumor regression by intratumoral STING agonists combined with anti-programmed death-L1 blocking antibody in a preclinical squamous cell carcinoma model.
Gadkaree SK; Fu J; Sen R; Korrer MJ; Allen C; Kim YJ
Head Neck; 2017 Jun; 39(6):1086-1094. PubMed ID: 28323387
[TBL] [Abstract][Full Text] [Related]
29. A 2D Nanoradiosensitizer Enhances Radiotherapy and Delivers STING Agonists to Potentiate Cancer Immunotherapy.
Luo T; Nash GT; Jiang X; Feng X; Mao J; Liu J; Juloori A; Pearson AT; Lin W
Adv Mater; 2022 Sep; 34(39):e2110588. PubMed ID: 35952624
[TBL] [Abstract][Full Text] [Related]
30. Sulfonated Perylene as Three-in-One STING Agonist for Cancer Chemo-Immunotherapy.
Zhao X; Zheng R; Zhang B; Zhao Y; Xue W; Fang Y; Huang Y; Yin M
Angew Chem Int Ed Engl; 2024 Mar; 63(11):e202318799. PubMed ID: 38230819
[TBL] [Abstract][Full Text] [Related]
31. Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants.
Dubensky TW; Kanne DB; Leong ML
Ther Adv Vaccines; 2013 Nov; 1(4):131-43. PubMed ID: 24757520
[TBL] [Abstract][Full Text] [Related]
32. STING and TLR7/8 agonists-based nanovaccines for synergistic antitumor immune activation.
Zhang BD; Wu JJ; Li WH; Hu HG; Zhao L; He PY; Zhao YF; Li YM
Nano Res; 2022; 15(7):6328-6339. PubMed ID: 35464625
[TBL] [Abstract][Full Text] [Related]
33. Discovery of BI 7446: A Potent Cyclic Dinucleotide STING Agonist with Broad-Spectrum Variant Activity for the Treatment of Cancer.
Kuttruff CA; Fleck M; Carotta S; Arnhof H; Bretschneider T; Dahmann G; Gremel G; Grube A; Handschuh S; Heimann A; Hofmann MH; Impagnatiello MA; Nar H; Rast G; Schaaf O; Schmidt E; Oost T
J Med Chem; 2023 Jul; 66(14):9376-9400. PubMed ID: 37450324
[TBL] [Abstract][Full Text] [Related]
34. Improving STING Agonist Delivery for Cancer Immunotherapy Using Biodegradable Mesoporous Silica Nanoparticles.
Park KS; Xu C; Sun X; Louttit C; Moon JJ
Adv Ther (Weinh); 2020 Oct; 3(10):. PubMed ID: 34295963
[TBL] [Abstract][Full Text] [Related]
35. Lipo/TK-CDN/TPP/Y6 nanoparticles inhibit cutaneous melanoma formation.
Xiao A; Yin L; Chen T; Qian H
J Drug Target; 2024 Jun; ():1-10. PubMed ID: 38838039
[TBL] [Abstract][Full Text] [Related]
36. Overcoming STING Agonists Barriers: Peptide, Protein, and Biomembrane-based Biocompatible Delivery Strategies.
Zheng YF; Wu JJ
Chem Asian J; 2022 Mar; 17(6):e202101400. PubMed ID: 35080118
[TBL] [Abstract][Full Text] [Related]
37. Chimeric Exosomes Functionalized with STING Activation for Personalized Glioblastoma Immunotherapy.
Bao P; Gu HY; Ye JJ; He JL; Zhong Z; Yu AX; Zhang XZ
Adv Sci (Weinh); 2024 Feb; 11(6):e2306336. PubMed ID: 38072677
[TBL] [Abstract][Full Text] [Related]
38. STING Activation and its Application in Immuno-Oncology.
Lian Y; Duffy KJ; Yang J
Curr Top Med Chem; 2019; 19(24):2205-2227. PubMed ID: 31642767
[TBL] [Abstract][Full Text] [Related]
39. Agonists and inhibitors of the STING pathway: Potential agents for immunotherapy.
Wu JJ; Zhao L; Hu HG; Li WH; Li YM
Med Res Rev; 2020 May; 40(3):1117-1141. PubMed ID: 31793026
[TBL] [Abstract][Full Text] [Related]
40. Discovery of IACS-8803 and IACS-8779, potent agonists of stimulator of interferon genes (STING) with robust systemic antitumor efficacy.
Ager CR; Zhang H; Wei Z; Jones P; Curran MA; Di Francesco ME
Bioorg Med Chem Lett; 2019 Oct; 29(20):126640. PubMed ID: 31500996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
